+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacogenomics Services Market by Genetic Testing Technology, Test Type, Application Areas, Pharmaceutical Development, Technology Platforms, Laboratory Automation - Global Forecast to 2030- Product Image
Pharmacogenomics Services Market by Genetic Testing Technology, Test Type, Application Areas, Pharmaceutical Development, Technology Platforms, Laboratory Automation - Global Forecast to 2030- Product Image
Sale

Pharmacogenomics Services Market by Genetic Testing Technology, Test Type, Application Areas, Pharmaceutical Development, Technology Platforms, Laboratory Automation - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6160254
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The pharmacogenomics services market has rapidly evolved from a promising concept into a critical component of precision medicine. Fueled by advances in genomic sequencing technologies and an increasing emphasis on personalized therapeutic regimens, this field is reshaping how clinicians approach patient care. Early adopters of pharmacogenomic testing have demonstrated improvements in drug efficacy, reductions in adverse drug reactions, and overall enhancements in patient outcomes. As healthcare systems worldwide strive to optimize resource utilization and meet rising patient expectations, pharmacogenomics is positioned as a cornerstone of value-based care. Recent regulatory endorsements and reimbursement frameworks have further legitimized routine genetic testing in clinical workflows, accelerating market adoption. Meanwhile, digital health platforms and bioinformatics tools are streamlining data interpretation and integration with electronic health records, making pharmacogenomics services more accessible to a broad range of healthcare stakeholders. Looking ahead, ongoing collaborations between diagnostic laboratories, pharmaceutical developers, and technology providers will drive the next wave of innovation. By understanding the market’s foundational drivers and barriers, decision-makers can capitalize on emerging opportunities to deliver tailored therapies, reduce healthcare costs, and improve population health.

Transformative Shifts Driving Pharmacogenomics Market Evolution

The pharmacogenomics market is undergoing several transformative shifts that are redefining its growth trajectory. Technological breakthroughs in next-generation sequencing, coupled with the advent of digital PCR, have enabled laboratories to generate high-resolution genomic data at unprecedented speed and scale. Simultaneously, artificial intelligence and machine learning algorithms are enhancing variant interpretation, accelerating biomarker discovery, and improving predictive testing accuracy. Cloud-based bioinformatics platforms are democratizing access to sophisticated analysis tools, enabling even smaller diagnostic centers to offer advanced services. Regulatory agencies are also playing a pivotal role by issuing clear guidelines that support clinical implementation of pharmacogenomic assays, thereby reducing adoption barriers. At the same time, value-based reimbursement models are incentivizing healthcare providers to leverage genetic insights to tailor therapies and minimize hospital readmissions. Patient advocacy groups and professional societies are championing standardized testing protocols and data-sharing initiatives, fostering greater collaboration across the healthcare ecosystem. These converging forces are propelling pharmacogenomics from a niche offering into a mainstream clinical tool, setting the stage for broader integration into standard care pathways.

Evaluating the Impact of New US Tariffs on 2025 Pharmacogenomics Services

The introduction of new United States tariffs on imported reagents, sequencing instruments, and laboratory consumables has created a ripple effect across the pharmacogenomics value chain. Increased duties on critical inputs have elevated operational costs for diagnostic laboratories, prompting many to renegotiate supplier contracts or pivot towards domestically manufactured alternatives. Equipment vendors are exploring local production partnerships to mitigate tariff-related price increases, while service providers are reengineering assay workflows to optimize reagent usage and reduce waste. Patients and payers are feeling the impact through modest upticks in testing fees, which in turn has intensified scrutiny on cost-effectiveness and reimbursement policies. In response, several key stakeholders are lobbying for tariff exemptions on life-science equipment, underscoring pharmacogenomics’ role in advancing public health. Despite these challenges, the market is adapting through strategic alliances and supply chain diversification. Organizations that proactively assess tariff implications and implement resilient procurement strategies are better positioned to maintain competitive pricing and service quality, safeguarding long-term growth in a more protectionist trade environment.

Comprehensive Segmentation Insights for Pharmacogenomics Services

The pharmacogenomics market can be dissected through multiple lenses to reveal distinct areas of opportunity. Based on genetic testing technology, providers are capitalizing on microarray analysis for high-throughput genotyping, while next-generation sequencing has emerged as the workhorse for comprehensive variant detection, with digital PCR enhancing quantitative precision. Polymerase chain reaction remains a rapid and cost-effective option for targeted screens, and Sanger sequencing continues to serve as the gold standard for confirmatory analysis. Looking at test type, diagnostic testing retains its stronghold in clinical decision support, predictive testing is gaining traction through advanced risk assessment tools, prognostic testing guides disease progression management, and therapeutic monitoring ensures dosage optimization over the course of treatment. Application areas span cardiovascular health, where genotype-guided antiplatelet therapy reduces adverse events; infectious diseases, leveraging host and pathogen genetics; neurological disorders, personalizing interventions for complex conditions; oncology solutions, tailoring targeted therapies; and rare diseases, driving early diagnosis and intervention. Within pharmaceutical development, adverse reaction profiling mitigates safety risks, clinical trials support accelerates biomarker identification and patient stratification, and drug metabolism analysis informs dosage design. Underpinning these segments are technology platforms such as bioinformatics tools, cloud-based solutions integrating artificial intelligence applications and machine learning algorithms, and high-throughput screening. Laboratory automation further streamlines workflows through automated sample preparation, integrated workflow systems, and robotic liquid handling, maximizing throughput and reducing error.

Key Regional Dynamics Influencing Pharmacogenomics Adoption

Regional dynamics are shaping the pharmacogenomics market in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, strong investments in genomic research infrastructure, coupled with favorable reimbursement policies, are driving widespread adoption of pharmacogenomic testing in both inpatient and outpatient settings. In Europe, Middle East & Africa, diverse regulatory landscapes are being harmonized through cross-border collaborations and the establishment of centralized genomic data repositories, accelerating multicenter trials and standardizing testing protocols. Meanwhile, Asia-Pacific markets are experiencing rapid growth due to increasing government funding for biotechnology initiatives, expanding healthcare coverage, and rising patient awareness of personalized medicine benefits. Local players across all regions are forging strategic partnerships to expand testing capacities and improve supply chain resilience. By navigating regional regulatory frameworks and tailoring value propositions to local healthcare priorities, service providers can unlock new revenue streams and drive sustained market penetration throughout these key geographies.

Leading Companies Driving Innovation and Market Expansion

A diverse array of companies is spearheading innovation and shaping market expansion in pharmacogenomics services. Adaptive Genomics Pharma Ltd., BioPharm Genomics Corp, CliniPharm Genetic Solutions LLC, EthnoPharm Genomics Inc. and GenePath Pharma Innovations LLC are expanding their sequencing capabilities, while GenePharm Solutions LLC, GeneTech Pharma Solutions LLC and Genetic Pharm Therapeutics Ltd. are focusing on integrated assay platforms. GeneWise Pharma Analysis Ltd., GenomeCure Diagnostics Ltd. and GenomeRx Ltd. lead efforts in clinical interpretation services, with Genomic Therapy Solutions LLC, Innovative GenePharma Inc. and Integrated Pharmagenomics LLC driving partnerships across the drug development continuum. MedGene Diagnostics Corp. and NextGen Pharm Diagnostics LLC are at the forefront of point-of-care testing, as OmicsPharm Solutions Inc., Personalized PharmaGen Inc. and Pharmaco Diagnostics Corp. innovate in predictive risk assessments. Pharmacogenetic Innovators Inc., PharmacoGenX Inc. and PharmaGen Insights Corp. are integrating AI-driven bioinformatics, while PharmaGenome Research Ltd., PharmAnalytics Group Inc. and PharmaOmics Inc. enhance data analytics for clinical trials. PharmGen Research Institute, PharmGene Clinical Research Corp. and PharmGenix Inc. are distinguished by their work in patient stratification, and Precision Genomics Solutions Inc. alongside PrecisionPharm Analytics Ltd. are pioneering cloud-based platforms optimized with machine learning. Collectively, these organizations are forging strategic alliances, investing in next-generation platforms, and standardizing workflows to accelerate market uptake.

Actionable Recommendations for Industry Leadership

To capitalize on evolving market dynamics and maintain competitive advantage, industry leaders should pursue several strategic initiatives. First, strengthening domestic manufacturing and local supplier partnerships can mitigate the impact of international trade tariffs and ensure continuity of critical reagents and equipment. Second, investing in cloud-native bioinformatics platforms integrated with AI and machine learning will enhance data analysis speed, scalability and interpretive accuracy. Third, fostering cross-sector collaborations between diagnostic labs, pharmaceutical developers and academic institutions will accelerate biomarker discovery and validation. Fourth, engaging proactively with regulatory bodies to shape reimbursement frameworks and standardization guidelines can facilitate broader clinical adoption. Fifth, prioritizing scalable laboratory automation investments-from robotic liquid handling to integrated workflow systems-will optimize throughput and reduce operational costs. Finally, expanding the focus on underserved segments, such as rare diseases and neurology applications, will unlock high-value niches and position organizations as market leaders in specialized pharmacogenomics services.

Conclusion: Embracing Pharmacogenomics for Next-Generation Personalized Care

Pharmacogenomics services are poised to redefine personalized healthcare by enabling data-driven therapeutic decisions, reducing adverse events, and enhancing patient outcomes. The convergence of advanced sequencing technologies, automation and cloud-based analytics is driving unprecedented growth, while evolving regulatory and reimbursement landscapes are facilitating integration into routine care. Despite challenges posed by trade tariffs and supply chain disruptions, proactive strategies in manufacturing, strategic partnerships and technological investments are unlocking resilient pathways for market expansion. As regional dynamics continue to shape adoption patterns, stakeholders who adapt their value propositions to local healthcare priorities will secure lasting competitive advantage. Collaboration between diagnostic providers, pharmaceutical developers and technology firms remains essential to fuel innovation, standardize testing protocols and accelerate the translation of genomic insights into clinical practice. By embracing these imperatives, organizations can contribute to a future where precision medicine is the norm rather than the exception, improving health outcomes on a global scale.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Genetic Testing Technology
    • Microarray Analysis
    • Next Generation Sequencing
      • Digital Pcr
    • Polymerase Chain Reaction
    • Sanger Sequencing
  • Test Type
    • Diagnostic Testing
    • Predictive Testing
      • Risk Assessment Tools
    • Prognostic Testing
    • Therapeutic Monitoring
  • Application Areas
    • Cardiovascular Health
    • Infectious Diseases
    • Neurological Disorders
    • Oncology Solutions
    • Rare Diseases
  • Pharmaceutical Development
    • Adverse Reaction Profiling
    • Clinical Trials Support
      • Biomarker Identification
      • Patient Stratification
    • Drug Metabolism Analysis
  • Technology Platforms
    • Bioinformatics Tools
    • Cloud Based Solutions
      • Artificial Intelligence Applications
      • Machine Learning Algorithms
    • High Throughput Screening
  • Laboratory Automation
    • Automated Sample Preparation
    • Integrated Workflow Systems
    • Robotic Liquid Handling
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Adaptive Genomics Pharma Ltd.
  • BioPharm Genomics Corp
  • CliniPharm Genetic Solutions LLC
  • EthnoPharm Genomics Inc.
  • GenePath Pharma Innovations LLC
  • GenePharm Solutions LLC
  • GeneTech Pharma Solutions LLC
  • Genetic Pharm Therapeutics Ltd.
  • GeneWise Pharma Analysis Ltd.
  • GenomeCure Diagnostics Ltd.
  • GenomeRx Ltd.
  • Genomic Therapy Solutions LLC
  • Innovative GenePharma Inc.
  • Integrated Pharmagenomics LLC
  • MedGene Diagnostics Corp
  • NextGen Pharm Diagnostics LLC
  • OmicsPharm Solutions Inc.
  • Personalized PharmaGen Inc.
  • Pharmaco Diagnostics Corp
  • Pharmacogenetic Innovators Inc.
  • PharmacoGenX Inc.
  • PharmaGen Insights Corp
  • PharmaGenome Research Ltd.
  • PharmAnalytics Group Inc.
  • PharmaOmics Inc.
  • PharmGen Research Institute
  • PharmGene Clinical Research Corp
  • PharmGenix Inc.
  • Precision Genomics Solutions Inc.
  • PrecisionPharm Analytics Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmacogenomics Services Market, by Genetic Testing Technology
8.1. Introduction
8.2. Microarray Analysis
8.3. Next Generation Sequencing
8.3.1. Digital Pcr
8.4. Polymerase Chain Reaction
8.5. Sanger Sequencing
9. Pharmacogenomics Services Market, by Test Type
9.1. Introduction
9.2. Diagnostic Testing
9.3. Predictive Testing
9.3.1. Risk Assessment Tools
9.4. Prognostic Testing
9.5. Therapeutic Monitoring
10. Pharmacogenomics Services Market, by Application Areas
10.1. Introduction
10.2. Cardiovascular Health
10.3. Infectious Diseases
10.4. Neurological Disorders
10.5. Oncology Solutions
10.6. Rare Diseases
11. Pharmacogenomics Services Market, by Pharmaceutical Development
11.1. Introduction
11.2. Adverse Reaction Profiling
11.3. Clinical Trials Support
11.3.1. Biomarker Identification
11.3.2. Patient Stratification
11.4. Drug Metabolism Analysis
12. Pharmacogenomics Services Market, by Technology Platforms
12.1. Introduction
12.2. Bioinformatics Tools
12.3. Cloud Based Solutions
12.3.1. Artificial Intelligence Applications
12.3.2. Machine Learning Algorithms
12.4. High Throughput Screening
13. Pharmacogenomics Services Market, by Laboratory Automation
13.1. Introduction
13.2. Automated Sample Preparation
13.3. Integrated Workflow Systems
13.4. Robotic Liquid Handling
14. Americas Pharmacogenomics Services Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Pharmacogenomics Services Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Pharmacogenomics Services Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Adaptive Genomics Pharma Ltd.
17.3.2. BioPharm Genomics Corp
17.3.3. CliniPharm Genetic Solutions LLC
17.3.4. EthnoPharm Genomics Inc.
17.3.5. GenePath Pharma Innovations LLC
17.3.6. GenePharm Solutions LLC
17.3.7. GeneTech Pharma Solutions LLC
17.3.8. Genetic Pharm Therapeutics Ltd.
17.3.9. GeneWise Pharma Analysis Ltd.
17.3.10. GenomeCure Diagnostics Ltd.
17.3.11. GenomeRx Ltd.
17.3.12. Genomic Therapy Solutions LLC
17.3.13. Innovative GenePharma Inc.
17.3.14. Integrated Pharmagenomics LLC
17.3.15. MedGene Diagnostics Corp
17.3.16. NextGen Pharm Diagnostics LLC
17.3.17. OmicsPharm Solutions Inc.
17.3.18. Personalized PharmaGen Inc.
17.3.19. Pharmaco Diagnostics Corp
17.3.20. Pharmacogenetic Innovators Inc.
17.3.21. PharmacoGenX Inc.
17.3.22. PharmaGen Insights Corp
17.3.23. PharmaGenome Research Ltd.
17.3.24. PharmAnalytics Group Inc.
17.3.25. PharmaOmics Inc.
17.3.26. PharmGen Research Institute
17.3.27. PharmGene Clinical Research Corp
17.3.28. PharmGenix Inc.
17.3.29. Precision Genomics Solutions Inc.
17.3.30. PrecisionPharm Analytics Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PHARMACOGENOMICS SERVICES MARKET MULTI-CURRENCY
FIGURE 2. PHARMACOGENOMICS SERVICES MARKET MULTI-LANGUAGE
FIGURE 3. PHARMACOGENOMICS SERVICES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PHARMACOGENOMICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PHARMACOGENOMICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PHARMACOGENOMICS SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY RISK ASSESSMENT TOOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY ONCOLOGY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY ADVERSE REACTION PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PATIENT STRATIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY DRUG METABOLISM ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY ARTIFICIAL INTELLIGENCE APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY AUTOMATED SAMPLE PREPARATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY INTEGRATED WORKFLOW SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACOGENOMICS SERVICES MARKET SIZE, BY ROBOTIC LIQUID HANDLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 77. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 79. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 80. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 81. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 82. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 83. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 84. CANADA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 87. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 89. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 91. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 92. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES PHARMACOGENOMICS SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 127. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 129. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 130. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 131. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 132. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 133. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 134. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 135. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 136. CHINA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 137. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 139. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 140. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 141. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 142. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 143. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 144. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 145. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 146. INDIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 157. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 159. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 160. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 161. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 162. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 163. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 164. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 165. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 166. JAPAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 217. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 218. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 219. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 220. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 221. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 222. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 223. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 224. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 225. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 226. THAILAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 250. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 251. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 252. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 254. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 255. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 257. DENMARK PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 258. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 260. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 261. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 262. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 263. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 264. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 265. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 267. EGYPT PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 268. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 270. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 272. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 273. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 274. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 275. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 276. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 277. FINLAND PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 278. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 279. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 280. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 281. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 282. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 284. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 285. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 286. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 287. FRANCE PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 288. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 290. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 291. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY PREDICTIVE TESTING, 2018-2030 (USD MILLION)
TABLE 292. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 293. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 294. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLINICAL TRIALS SUPPORT, 2018-2030 (USD MILLION)
TABLE 295. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
TABLE 296. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY CLOUD BASED SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 297. GERMANY PHARMACOGENOMICS SERVICES MARKET SIZE, BY LABORATORY AUTOMATION, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL PHARMACOGENOMICS SERVICES MARKET SIZE, BY GENETIC TESTING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL PHARMACOGENOMICS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL PHARMACOGENOMICS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL PHARMACOGENOMICS SERVICES MARKET SIZ

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pharmacogenomics Services market report include:
  • Adaptive Genomics Pharma Ltd.
  • BioPharm Genomics Corp
  • CliniPharm Genetic Solutions LLC
  • EthnoPharm Genomics Inc.
  • GenePath Pharma Innovations LLC
  • GenePharm Solutions LLC
  • GeneTech Pharma Solutions LLC
  • Genetic Pharm Therapeutics Ltd.
  • GeneWise Pharma Analysis Ltd.
  • GenomeCure Diagnostics Ltd.
  • GenomeRx Ltd.
  • Genomic Therapy Solutions LLC
  • Innovative GenePharma Inc.
  • Integrated Pharmagenomics LLC
  • MedGene Diagnostics Corp
  • NextGen Pharm Diagnostics LLC
  • OmicsPharm Solutions Inc.
  • Personalized PharmaGen Inc.
  • Pharmaco Diagnostics Corp
  • Pharmacogenetic Innovators Inc.
  • PharmacoGenX Inc.
  • PharmaGen Insights Corp
  • PharmaGenome Research Ltd.
  • PharmAnalytics Group Inc.
  • PharmaOmics Inc.
  • PharmGen Research Institute
  • PharmGene Clinical Research Corp
  • PharmGenix Inc.
  • Precision Genomics Solutions Inc.
  • PrecisionPharm Analytics Ltd.

Related Topics

Related Reports

Pharmacogenomics Market by Therapeutic Area (Cardiology, Infectious Diseases, Neurology), Product (Consumables, Services, Software and Platforms), Technology, End User, Test Type, Biomarker Type - Global Forecast 2025-2030 - Product Image

Pharmacogenomics Market by Therapeutic Area (Cardiology, Infectious Diseases, Neurology), Product (Consumables, Services, Software and Platforms), Technology, End User, Test Type, Biomarker Type - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031 - Product Image

Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031

  • Report
  • 210 Pages
  • Global
From
Predictive Genetics Market by Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Test Type (Cancer Screening, Carrier Screening, Pharmacogenomics), Application, End User, Product Type - Global Forecast 2025-2030 - Product Image

Predictive Genetics Market by Technology (Microarray, Next Generation Sequencing, Polymerase Chain Reaction), Test Type (Cancer Screening, Carrier Screening, Pharmacogenomics), Application, End User, Product Type - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Forecast to 2028 - Product Image

Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Forecast to 2028

  • Report
  • 381 Pages
  • Global
From
Gene Panel Market by Product Type (Custom Panels, Platform, Predesigned Panels), Technology (Microarray, Ngs, Pcr), Application, End User - Global Forecast 2025-2030 - Product Image

Gene Panel Market by Product Type (Custom Panels, Platform, Predesigned Panels), Technology (Microarray, Ngs, Pcr), Application, End User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.